a new strategy for eliminating autoantigen-selected B cells and for treating early lymphoblastic leukemias and/or lymphomas was developed using CD19-specific mAbs that induce Fcγ receptor ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback